Figure 2

Upregulation of Fmr1 gene expression upon pirenperone treatment (A) FMR1 gene expression was significantly down-regulated in human FXS patients. Unpaired t-test. Control versus FXS, ***p < 0.001 (B) Fmr1 gene expression level was significantly up-regulated after pirenperone treatment at a dose of 20 μM in cortical neuron. (C) Gene expression level for ATRNL1 in human patients (left) and real-time PCR result in cultures (right). (D) Gene expression level for SETBP1 in human patients (left) and real-time PCR result in cultures (right). (E) Gene expression level for ROBO11 in human patients (left) and real-time PCR result in cultures (right). (F) Gene expression level for CHL1 in human patients (left) and real-time PCR result in cultures (right). (G) Gene expression level for LAMB1 in human patients (left) and real-time PCR result in cultures (right). (H) Gene expression level for RIMS3 in human patients (left) and real-time PCR result in cultures (right). (I) Gene expression level for ANK3 in human patients (left) and real-time PCR result in cultures (right). One-way ANOVA, post hoc test: Bonferroni’s multiple comparison test, Vehicle versus 20 μM, ***5 μM versus 20 μM, ^###10 μM versus 20 μM, ^@@@p < 0.001, number of samples per group = 12. (J) Gene expression change after treatment of pirenperone. Color in the circle represents expression difference between the pirenperone and vehicle treatment (red: higher expression in pirenperone, grey means no difference). The thickness of edges represents the number of supporting evidence of a co-expressional relationship between genes.